Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
News|Articles|June 3, 2026
Eli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Report
Author(s)Nicholas Jacobus
Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating a months-long standoff with the American Hospital Association and prompting calls for federal intervention.
Advertisement
Advertisement
Eli Lilly moved to cut off
Related to this article
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
Advertisement
Advertisement